AIM ImmunoTech (AIM) vs Liminatus Pharma (LIMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AIM ImmunoTech is the larger company by market cap ($7.2 million vs $5.0 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | LIMN |
|---|---|---|
| Share price | $0.1796 | $3.69 |
| Market cap | $7.17M | $4.96M |
| 1-day change | -1.75% | -4.65% |
| EPS (TTM) | $-2.98 | $-23.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $141.50 |
| 52-week low | $0.17 | $3.29 |
| Distance from 52-week high | -93.57% | -97.39% |
| Analyst consensus | none | — |
| Avg. price target upside | +2266.37% | — |
| Average volume | 4.70M | 453.28K |
| Shares outstanding | 39.89M | 1.34M |
| Employees | 19 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1 employees
AIM vs LIMN FAQ
Which is bigger, AIM ImmunoTech or Liminatus Pharma?
AIM ImmunoTech (AIM) is larger, with a market capitalization of $7.17M compared with $4.96M for Liminatus Pharma (LIMN).
Are AIM ImmunoTech and Liminatus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.